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Summary 
The MTEP committee presented 4 technical questions on HumiGard, and these have been addressed 
using literature reviews, company documentation and a user survey. 
The information reviewed by Cedar includes a literature search, user questionnaires and company 
test data. Our review leads to the following conclusions: 
 There may be some tissue discolouration visible when using HumiGard in open surgery, but 
trained users do not find this problematic. 
 There is no reason to believe that HumiGard adds undue complexity or restricts the field of 
vision during open surgery. 
 The single use nature of the administration set, and the use of filters makes it unlikely that 
HumiGard will cause bacterial contamination during surgery. The administration set is not 
entirely sterile, meaning that there is a possibility of contamination entering the system 
during setup. The company has submitted a test report to demonstrate that bacteria are not 
transmitted from the reservoir or sensor to the patient. No evidence has been identified that 
indicates any increase in infection rates.  
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What is HumiGard? 
HumiGard is a device for warming and humidifying CO2 that is being supplied to the surgical site 
either for insufflations of a laparoscopic procedure, or as part of open surgery. In abdominal open 
surgery this is for patient warming, in cardiac open surgery it also performs the role of de-airing. 
The HumiGard has several components: 
 The machine that is reusable and has a “hot-plate” on which the water container is warmed 
 Reusable sensor for temperature, flow and ambient conditions 
 The single use procedure pack that contains: 
o CO2 delivery tube, from CO2 device to HumiGard water container, with filter 
o HumiGard water container, which acts as the humidification chamber 
o Sterile tube for delivery of warm, humidified CO2 from HumiGard to the patient 
 Sterile water is added to the water container at the start of the procedure. The company 
advised that water temperature is typically 43-54 °C during use. 
 
Questions from MTEP committee, and general approach 
Three general approaches were used to answer questions 1 to 4.  
A literature search was carried out using Medline, Medline in process and Embase. One literature 
search was used to address all the questions; with differentiation during the selection process. A 
total of 390 papers, conference abstracts and posters were identified. From these 32 were selected 
in the first sift of literature. Further selections were then made for each question, The company also 
provided relevant references, including 5 that had not been identified in the literature search, either 
due to being very recent abstracts, or not being well indexed in the databases.  
In addition, background information and information on devices that work by a similar mechanism, 
but for different clinical purposes, was searched for question 3. This search was systematic, using 
Figure 1 HumiGard system (image courtesy of Fisher and Paykel, labelling by Cedar) 
HEPA Filter for 
CO2 
Tubing for 
dry CO2 
Humidification chamber 
containing  sterile water 
Sterile tube for 
delivery of 
humidified CO2 to 
patient 
900ST100 Adaptor, 
with temperature and 
flow sensors. 
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Medline, but due to the broad nature of the question was not a full systematic review. The company 
that produces the CO2 diffuser lists relevant technical papers on their website and these were 
reviewed for the response to Q4. 
Company documentation such as CE marking certification and instructions for use were examined. 
The company also gave commercial in confidence access to test reports that had been completed by 
a third party.  
An electronic user questionnaire was sent to 17 clinicians who use HumiGard during open surgery, 
as identified by the company. They included 6 users at 4 sites in the UK, 8 users at 4 sites in 
Australia, 1 user from New Zealand and 1 user from Sweden. The name of one additional clinician in 
Australia was provided but no e-mail address has been identified for this contact. Seven responses 
were received, including 3 from the UK. A pdf of the user questionnaire, with the responses, is 
included at the end of the report in  Appendix 1.  
All responders indicated that they are happy to be contacted with further questions if they arise, and 
Cedar contacted them to clarify issues for Q3 regarding bacterial contamination. 
1 Does HumiGard cause tissue discolouration in open surgery of a 
similar appearance to tissue ischaemia? 
Cedar identified 3 papers and 1 poster (Frey et al. 2012a, Frey et al. 2012b, Frey et al. 2010, 
Weinburg et al. 2015) describing the use of HumiGard in open surgery, plus 1 additional paper 
(Svernarud et al 2004) and 1 poster (El-Gamel et al. 2015a) identified by the company. El-Gamel et al 
have shared their manuscript as academic in confidence (El-Gamel et al. 2015b). None of these 
mention tissue discolouration. 
From the user questionnaire (responses =7) 1 user had noticed tissue discolouration, and the same 
user said that colleagues noticed tissue colouration. This user felt that it was a training issue, stating: 
Q8. “Early use with device needed training and understanding of the colour changes when peritoneal 
cavity was exposed to humidified CO2. This would not stop me using the device” 
Q13: “This is transient and simply needs training.” 
Q16: “This discolouration was not indicative of serious harm/ problem but potentially may make 
differentiating ischaemic non viable tissues from viable tissue difficult. I do not think this is an 
insuperable problem” 
6 users said neither they nor colleagues had noticed tissue discolouration. 1 user said that blood in 
the abdomen could have a darker colour when using HumiGard. 
1 user felt that discolouration could theoretically be mistaken for ischaemia (although they had not 
noted it), and 2 users felt that it could be mistaken for ischaemia only by new users.  
None of the users felt that there was a problem with any discolouration, and stated that there was 
no concern related to the discolouration.  
 
 
Page 5 of 17 
 
HumiGard: Technical Evaluation 
Final Report November 2015 
The full survey responses are included in Appendix 1 at the end of the report.  
2 Does the use of HumiGard in open surgery result in added 
complexity or reduce access or visibility? If so, does this have an 
impact on its acceptability to surgeons when used during open 
surgical procedures? 
Cedar examined 3 papers , 2 posters and 1 draft manuscript (Frey et al. 2012a, Frey et al. 2012b, 
Frey et al. 2010 , El-Gamel et al. 2015a, El-Gamel et al.2015b, Weinburg et al. 2015) describing the 
use of HumiGard in open surgery. Frey et al. (2012a) mention in the discussion that surgeons did not 
find that the diffuser used with HumiGard got in the way. The remaining literature did not discuss 
usability. 
The user questionnaire results, for open surgery, were: 
Question 20: Please answer the following questions 
for open surgery   (n=7) 
Agree Mildly 
agree 
Mildly 
disagree 
Disagree 
Using HumiGard adds complexity to the surgical 
procedure 
0 0 1 6 
HumiGard does not reduce visibility 7 0 0 0 
I find HumiGard easy to use 6 1 0 0 
 
When asked what drawbacks there might be to using HumiGard during open surgery, 3 respondents 
said there were none, the other four responses were: 
“Theatre teams need to be trained to use this equipment. This is part of a bundle of team training 
and human factors” 
“ETCO2 may be slightly elevated. This is mild and can be easily managed by adjusting minute 
ventilation.” 
“Positioning in the abdomen can be difficult and sometimes difficult to cover the whole open 
abdomen but very good in the chest as it sits nicely away from where you are working and works on 
while thoracic cavity [SIC]” 
“Catheter can get displaced” 
The full survey responses are included in Appendix 1 at the end of the report.  
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3 Bacterial infection and associated biofilms 
3.1 Does the use of HumiGard result in increased risk of bacterial infection 
and associated biofilms forming in the areas of the device exposed to 
water? 
3.1.1 What is a biofilm and how might bacteria be transmitted? 
Biofilms occur when microorganisms attach to surfaces and are made up of microbial cells and an 
extracellular polymeric substance (EPS) matrix. In this environment genetic transfer between cells 
occurs readily; where resistance to antibiotics may be transferred to other cells through conjugation 
or DNA uptake. The EPS is thought to be a major component of the resistance of biofilms to a range 
of antimicrobial compounds and is thought to impede the mass transport of antibiotics through the 
biofilm. From a public health perspective biofilms are a problem. Detachments of viable cells or 
aggregates can result in infections; while their architecture gives rise to a markedly reduced 
susceptibility to antimicrobial agents and antibiotic resistance genes may be exchanged between 
microbes (Donlan 2002). If a medical device is contaminated with microorganisms there are several 
variables that will determine whether a biofilm develops or not. Donlan (2001) states that “first 
microorganisms must adhere to the exposed surfaces of the device long enough to become 
irreversibly attached”. These variables according to Donlan include the number of cells in the liquid 
to which the device is exposed, the flow rate of the liquid through the device and the physiochemical 
properties of the device surface. Mulla and Revdiwala (2011) state that once these cells have 
become irreversibly attached and produce EPS to develop a biofilm the rate of growth is “influenced 
by flow rate, nutrient composition of the medium, antimicrobial drug concentration, and ambient 
temperature”. In their work Feldman et al. (1999) have shown that endotracheal tube colonisation 
(biofilm formation) begins after 12 hours and is most abundant after 96 hours and this colonisation 
commonly gives rise to nosocomial pneumonia.  
The HumiGard is a humidifying device and while the temperature could potentially provide suitable 
conditions for microbial growth; the procedure times are unlikely to reach 12 hours. In addition, 
endotracheal tubes are subjected to microbial contamination from the patient. For HumiGard 
equipment during open surgery there is unlikely to be any risk of contamination into the device from 
the patient. For laparoscopic surgery it may be possible to have flow back into the device from the 
patient if there is any external pressure on the abdomen, but this will be much less probable than in 
endotracheal tubes. 
3.1.2 Water vapour, droplet nuclei and aerosol 
HumiGard generates humidity and heat for use with a CO2 insufflator. When water is heated in the 
HumiGard reservoir, it starts to evaporate, releasing water molecules as vapour. Any particles such 
as bacteria, that are in the liquid, remain in the liquid water. However if water droplets are formed 
as an aerosol, bacteria may be carried by these. When aerosols are formed, some remain as droplets 
and travel relatively short distances, others evaporate and form droplet nuclei where bacteria can 
remain airborne for several hours. Tang et al. (2006) state that aerosols are “a suspension of solid or 
liquid particles in a gas” and that “infectious aerosols contain pathogens”. In addition they describe a 
droplet nucleus as “the airborne residue of a potentially infectious (micro-organism-bearing) aerosol 
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from which most of the liquid has evaporated”. If the water in the reservoir is undisturbed and the 
only mechanism for water entering the CO2 stream is by evaporation, then bacteria cannot move 
from the water to the patient. If water droplets can be formed, (ie due to the surface being 
disturbed by a high gas flow) then bacteria may be transmitted, if they are present. 
3.1.3 Evidence relating to similar devices 
A similar design of humidifier has been used for many years for warming and humidifying gas 
delivered from mechanical ventilators. There are numerous studies investigating possible 
associations between ventilation, contamination and pneumonia. There are many factors in the 
ventilation circuit clinical set up that makes these inapplicable for HumiGard. These include the 
length of time that ventilation circuits are left in situ, the use of endotracheal tubes and the 
likelihood of contaminants travelling from the patient back to the device. 
Cedar identified three non-clinical studies that looked particularly at the transmission of particles 
found in humidifier reservoirs to the patient connected part of the circuit. None of these use the 
HumiGard device, and may not be directly applicable. 
Wenzel et al. (2005) investigated the need for sterile water in humidifiers, in order to avoid 
respiratory tract infections during nasal continuous positive airway pressure (nCPAP) therapy. A 
Sirius convection heated humidifier was used where the gas passes over the surface of the heated 
water, in a similar method to HumiGard. 400ml of water in the reservoir was radioactively labelled 
with 400 MBq 99mTc- diethylentriamine penta-acetic acid (DTPA), as a surrogate for bacterial 
contamination. Testing was carried out first with oxygen at flow rates of 2 l/min, 4 l/min, and 6 
l/min). Testing was then continued with air at flow rates of 31 l/min and 46 l/min. Tests were run for 
10 minutes, and 7 humidifiers were tested.  
A positive control was used where aerosols were generated and the filter was seen to collect and 
detect all of the radioactivity. However, no radioactivity was detected during testing of oxygen flow 
rates of 2 l/min, 4 l/min, and 6 l/min and no radioactivity was detected during nCAP at rates of 31 
l/min and 46 l/min. The authors surmise that water in the humidifier is not aerosolised and only 
produces water vapour, with solutes remaining in the liquid. Furthermore, due to the much smaller 
size of molecules of 99mTc-DTPA compared to bacteria they conclude that it’s highly unlikely 
bacteria would be aerosolised and carried in this manner.  
Ortolano et al. (2007) noted that the use of heated humidifiers during nCPAP, particularly if not 
cleaned, increases the risk of respiratory infections. Therefore, they conducted experiments in order 
to determine whether the water in a heated humidifier can be aerosolised and therefore pose an 
infection risk. 11 trials of heated humidifiers for nCPAP were conducted in total. Humidifier water 
was contaminated with 350 ml of Brevundimonas diminuta and Serratia marscens at an anticipated 
concentration of 5 to 10 x 107 CFU/ml. Humidifiers were set at 37°C and were monitored over a 
week. Bacteria were recovered from the breathing tubes of 9 humidifiers at around 103 CFU/ml at a 
flow rate of 60 l/min. The authors concluded that the humidifiers in the study aerosolised bacteria 
allowing them to be recovered from the breathing tubes. This study is in contradiction to the 
conclusions of Wenzel et al (2005). The flow rate in this study is higher than used by Wenzel, and 
both studies use considerably higher flow rates than typically used for HumiGard. The maximum 
output flow stated in HumiGard instructions for use is 15 l/min, and 10 l/min is quoted in some 
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studies (Frey et al 2012a, Svenarud et al 2004), or lower at 6.5l/min in others (Herrmann and de 
Wilde 2014). It is plausible that high flow rates may disturb the liquid surface in the reservoir and 
cause aerosols to form. The duration of the study is one week, which is a clinically valid time length 
for studying ventilation, however the HumiGard delivery circuit is single use and is only used for the 
duration of a single operation in theatre.  
Greib et al. (2008) studied the use of humidifiers to carry the anaesthetic Ropivacine at 0.75% and 
0.2%. Different humidifiers were tested in this experiment including a cold evaporating device, a 
nebulizer and 2 hot (50°C) evaporating devices each at a flow rate of 3 l/min. The results showed 
that neither of the hot evaporating devices carried the anaesthetic, and the cold evaporating device 
carried an extremely small amount (<0.0001%), while the nebulizer delivered 89.1% of 0.2% 
Ropivacaine, and 93.7% of 0.75% Ropivacaine. While this study did not measure bacterial 
contamination it adds further evidence that water vapour is unable to carry solutes while 
aerosolised water can. 
3.1.4 HumiGard components, sterility and cleaning 
HumiGard is made up of a reusable surgical humidifier (MR860), an adapter for temperature, flow 
and ambient sensing (900ST100) and a single-use laparoscopic humidification kit (ST310).  
 The single-use laparoscopic humidification kit contains:  
 a. Sterile components - gamma irradiated, in accordance with ISO11137 (sterilisation of health care 
products – radiation), supplied in sterile packaging 
 the tube that connects the humidifier to the patient 
b. Non-sterile components  
 HEPA filter (independently tested for bacterial and viral filtration efficiency) 
 Tubing between filter and reservoir 
 Reservoir 
 Funnel and adaptors 
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Components 
 (from CO2 supply 
towards patient) 
Single 
Use 
Sterile Additional information (from instructions for use and 
communication with company) 
Filter   0.3 µm HEPA filter 
Tubing   Bioburden tested (ISO 11737-1:2006) 
Reservoir   
Water (not included 
in kit) 
   
HumiGard device   This is not in contact with CO2 or water.  
Cleaning: with either Isopropyl alcohol or dishwashing 
detergent. 
900ST100 Adaptor:   The main body of the adaptor is not in contact with CO2 or 
water, however the temperature probe is inserted into the 
elbow of the sterile tubing.  
Cleaning: If visible matter is seen on the 900ST100 Adaptor, 
wipe clean with an alcohol swab 
Tubing    Sterilised using gamma radiation in accordance to ISO11137 
Sterilisation of Healthcare products – radiation. 
CarbonVITA diffuser 
(for open surgery, 
not included in kit) 
  Supplied sterile separately 
Figure 3 Non-sterile components (image 
courtesy of Fisher and Paykel) 
Figure 2 Sterile component (image courtesy 
of Fisher and Paykel) 
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The CO2 passes through the HEPA filter (specified as a bacterial and viral filtration efficiency of 
99.9999%). It then passes along tubing and into the top of the water reservoir. The water is warmed 
by the MR860 humidifier, causing evaporation of water molecules which humidifies the CO2. The 
humidified CO2 passes over the temperature sensor and along the sterile tubing to the patient. The 
temperature of the delivered CO2 is controlled by the temperature sensor by feedback to the 
humidification chamber. The humidified CO2 may be delivered via an insufflation port for 
laparoscopic surgery, or a CarbonVITA diffuser for open surgery 
There is very little potential for the build-up of biofilm within the HumiGard system, as the humid 
gas is only in contact with single use components, with the exception of the temperature probe. 
During open surgery there is unlikely to be flow back into the device from the patient. During 
laparoscopic surgery it may be possible to have flow back from the patient to the device if there is 
any external pressure on the abdomen. 
There is potential for bacteria or other contaminants to be introduced into the HumiGard system, as 
several components are not sterile, and also set up and filling the reservoir may allow the 
introduction of contaminants. For this to reach the patient, the bacteria would have to be 
transmitted via the humidified CO2.  
3.1.5 Device testing commissioned by Fisher and Paykel 
The company provided a signed statement that the HumiGard sterile components are compliant 
with ISO 11137-1:2006 and ISO 11137-1:2013 Sterlization of health care products – Radiation, parts 
1 & 2. The company stated “process monitoring and  bioburden testing on this product is performed 
on a regular basis. The testing is conducted in accordance with ISO11737 [ISO 11737-1:2006 
Sterilization of medical devices. Microbiological methods. Determination of a population of 
microorganisms on products]. Results are reviewed and trended against defined action limits. If the 
action limits were to be breached an investigation would commence as per the documented 
reaction plan.  The quality management system and manufacturing processes are audited annually 
by TUV SUD”.  Cedar have seen certification for the full quality assurance system audit in accordance 
with Medical Device Directive (MDD) Annex II, required for CE marking, by TUV-SUD (notified body 
number: 0123). The audit was carried out in March 2015, and is valid until March 2020.  
The air filter in the laparoscopic humidification kit is supplied by Air Safety Limited. This filter is a 
pleated mechanical 0.3 µm high-efficiency particulate arrestance (HEPA) filter, with 99.9999% 
bacterial filtration efficiency (BFE) and viral filtration efficiency (VFE). Testing of this filter is carried 
out independently. The humidified insufflator tube is also sterile so must be handled with correct 
aseptic technique.  
Fisher and Paykel provided a test report by the Centre for Pharmaceutical Research, University of 
South Australia investigating the risk of bacteria reaching the patient from either contamination of 
the probe or the water. 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
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XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXX 
3.1.6 User opinions 
Additional questions were sent to the 7 users who had replied to the questionnaire, 5 responses 
were received. They were asked if they were aware of any issues caused in practice by the use of 
non-sterile components, and if they thought it was possible for bacteria to be transmitted via the 
CO2 flow. The respondents generally agreed that they were not aware of any issues with this in 
practice, but that it may be possible for contamination to occur in this way. One replied that in a 
small study of 22 patients undergoing liver transplants, no infections had occurred in either the 
intervention or control group.  
3.1.7 Literature 
Cedar examined 4 papers, 2 posters and 1 draft manuscript (Frey etal. 2012a, Frey et al.2012b, Frey 
et al. 2010 , El-Gamel et al. 2015a, El-Gamel et al.2015b, Weinburg et al. 2015) that compared the 
use of HumiGard with no insufflation for open surgery in clinical trials. None reported infections 
rates in their outcomes. 
19 papers, abstracts or posters were identified that reported the use of warm, humidified 
insufflation gas in laparoscopic procedures. One additional paper was identified from the company 
submission (Herrmann and de Wilde 2015). Alternative devices were not searched for, however 
some were identified during the search. From the 19 papers or abstracts, 10 used HumiGard as the 
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intervention, but these only related to 5 separate studies (Yu et al. 2013, Herrmann and de Wilde 
2015, Noor et al. 2015, Sammour et al. 2010, Manwarring et al. 2008). Of the remaining papers, 6 
were concerning an alternative device (Insuflow), including 1 letter, and 3 were reviews or meta-
analysis.  
Two abstracts specifically address infection rates (Noor et al. 2015, Mason et al. 2015) during 
laparoscopic surgery. Both authors are based at Colchester Hospital, and appear to report on the 
same patient group. Noor et al. found that in a retrospective cohort study of 252 patients, the 
incidence of secondary site infection was significantly reduced from 12% to 4.7% following 
introduction of HumiGard (p = 0.047). Mason considered the cost effectiveness of the intervention. 
One paper (Farley et al. 2004) used an alternative device for humidification (RCT, n=101) and 
reported one case of infection in each group during a question and answer section at the end of the 
paper. 
The remainder of the papers and abstracts do not report infection rates. 
3.2 Is there any evidence that HumiGard can promote the spread of bacteria 
during a surgical procedure? 
Cedar examined 4 papers , 2 posters and 1 draft manuscript (Frey et al. 2012a, Frey et al. 2012b, 
Frey et al. 2010 , El-Gamel et al. 2015a, El-Gamel et al. 2015b, Weinburg et al. 2015) describing the 
use of HumiGard in open surgery. None of these reported infection rates.  
During open-surgery, a diffuser is used as an alternative to an open-ended tube that has been 
commonly used. The VITA-diffuser by Cardia Innovation AB has been specifically designed to be used 
in conjunction with the single-use laparoscopic humidification kit produced by Fisher & Paykel. 
Persson and Van der Linden (2004) have evaluated whether the diffuser influences the rate of 
airborne contamination of the cardiothoracic wound through the use of agar plates and a 
cardiothoracic wound cavity model. In total 3 experiments were designed in order to compare the 
rate of airborne contamination in an open-ended tube versus the diffuser, air versus carbon dioxide 
and carbon dioxide flow through the diffuser at 5 l/min versus 10 l/min. Briefly, the diffuser showed 
a decrease in airborne contamination with both air and carbon dioxide compared with the open-
ended tube. However, airborne contamination was lower when using the diffuser with carbon 
dioxide than when used with air. Finally, a carbon dioxide flow rate of 10 l/min through the diffuser 
showed a decreased contamination rate. 
Microbiological analysis of the effect of carbon dioxide on the growth of Staphylococcus aureus, a 
Gram positive organism that is frequently found as part of the normal human skin flora, has been 
previously carried out (Persson et al. 2005). S. aureus can cause skin infections, abscesses and 
endocarditis in addition to a whole range of other infections. In addition, methicillin resistant S. 
aureus (MRSA) can cause severe nosocomial infections due to its difficulty to treat. Persson et al. 
(2005) have examined the effect of incubating cultures of S. aureus on blood agar plates for 24 hours 
in the presence of air, anaerobic gas and carbon dioxide. S. aureus incubated in the presence of 
carbon dioxide showed a ~2-log10 reduction than in anaerobic gas (p=0.001) and a ~3-log reduction 
than in air (p=0.001). Furthermore, broth cultures of S. aureus insufflated separately with carbon 
dioxide and air were compared. Following 8 hours of insufflation, cultures insufflated with carbon 
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dioxide showed viable counts (CFU/ml) which were ~3-log10 lower than air (p=0.003). The results 
from these experiments suggest that the use of carbon dioxide as an insufflation gas could lower the 
numbers of S. aureus, a potentially pathogenic commensal skin organism. It must be noted that the 
results of this experiment show the effect of CO2 on S. aureus alone. These results therefore, may 
not be directly applicable to other potentially pathogenic bacteria of the human skin microbiome in 
addition to contamination from other sources. However, the results do show the inhibition of 
growth of a common commensal of the human skin microbiome which has the potential to be 
pathogenic.  
4 Is the mechanism of action of heated, humidified carbon dioxide 
different for open surgery compared to laparoscopic surgery? 
The device works in the same way for each type of surgery. The differences are the delivery method 
to the operative site. For open surgery the heated, humidified CO2 is delivered by a diffuser device 
that is placed at the edge of the wound area. This device was developed and is manufactured by 
Cardia, a group based at an academic institution in Sweden. This group have published multiple 
papers including bench testing, computer simulations and a randomised controlled trial (Frey et al. 
2012).  
4.1.1 Distribution and flow of CO2 in the open wound 
Cater and van de Linden, 2015: A finite element computer simulation is used to model the flow of 
CO2 from a diffuser placed in an oval shape representing an open surgical wound. The wound model 
is initially placed flat, and then placed at different angles from 0 to 22.5°. Cater and van de Linden 
found that the denser CO2 filled the entire wound model, and once this was full to the surface, the 
CO2 overflowed from the lowest point. At 10l/min the wound was full after approximately 6 seconds. 
The authors concluded that “a flow rate of 10l/min was sufficient to maintain a warm carbon dioxide 
barrier for a moderately sized surgical incision for all likely angles of inclination”.  
Persson and van de Linden, 2004: This experiment took place in an operating theatre, with a clean 
air ventilation system running. Particle contamination (5µm and larger) was measured on the 
operating table, and within a wound model on the table, when two surgeons (dressed as if working 
in theatre) stood by the operating table. No particles were detected at all. The surgeons then moved 
around the operating theatre, and pretended to carry out surgical tasks. When there was no CO2, a 
median of 18 particles per 0.1 cu ft, were detected (25th and 75th percentiles, 12 and 22.25). When 
using humidified CO2, a median of only 1 particle per 0.1 cu ft, was detected (25
th and 75th 
percentiles, 0 to 1.25; P < 0.001). No significant difference was found without the cavity. 
The rate of CO2 supplied was 10 l/min, there were 20 tests for each scenario. Charnley–Howorth 
ventilation system (Exflow Clean Zone 25S) was used in the operating theatre. Particles were 
detected using a particle counter (Met One 237A, Pacific Scientific Instruments, Grants Pass, OR).  
4.1.2 Carbon Dioxide to keep the open surgical wound warm  
Topical Humidified Carbon Dioxide to Keep the Open Surgical Wound Warm; Persson, Elmqvist et 
al 2004. 
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This reports a laboratory test where the surface temperature and evaporation rate from a wound 
model was measured during 5 tests, both with theatre lights on and off: 
 No insufflations (control) 
 Air at 5 l/min dry and humidified 
 CO2 at 5 l/min dry and humidified 
Humidification was from a bubble type humidifier (Aquapak 340 ml; HudsonRespiratory Care) 
heated to room temperature only. HumiGard was not used, the company has informed Cedar that 
the reservoir water temperature would normally be between 43 to 54 °C . When the theatre lights 
were on, the control surface temperature was 33.3 C, the surface temperature using air insufflation 
was slightly higher for both dry (p=0.03) and humidified (p=0.05) air. The actual temperatures 
measured were approximately 33.5°C (shown only as a graph). The surface temperature using dry 
CO2 insufflation was higher (35.2 °C) than the control and dry air (p>0.001). Humidified CO2 resulted 
in a surface temperature significantly higher than dry CO2 (35.6°C, p=0.002) 
The authors suggest that there are two mechanisms for the higher surface temperature and lower 
evaporation rate seen when using CO2. One is that CO2 and water vapour are both greenhouse 
gases, and they suggest that radiant heat from the body is absorbed by the gases to maintain a 
warmer layer over the wound. This will depend on the infrared wavelength radiating from the 
wound model being a wavelength that is absorbed by CO2. The relevance to a clinical effect will also 
depend if the wavelength of infrared emitted by a human body is absorbed by CO2. The second 
mechanism suggested is that because CO2 is denser than air, it may fill the wound cavity and reduce 
convection at the wound site (Cater and van der Linden 2015, Persson and van der Linden 2004). 
The experimental set up used the humidifier at room temperature to avoid any condensation. This is 
probably not reflective of normal practice and will have reduced the humidity of the gases delivered 
to the wound site. This may explain the relatively small effect on temperature and evaporation seen 
when increasing humidity.  
Papers discussing the use of HumiGard during cardiac surgery to reduce the risk of air microemboli 
were not included since cardiac surgery is outside the MTEP scope. 
Papers discussing the use of CO2 to deliver gaseous antiseptic or other gaseous substances during 
open surgery were not included since this is not part of normal practice at the current time.  
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Appendix 1 
Double click the icon to view the survey results. The user survey results are also provided as a separate 
document. 
Appendix 1 User 
Survey Results
 
